| Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838) |
|---|
| 01/29/2004 | US20040018177 Vacination method |
| 01/29/2004 | US20040018174 Cell therapy for regeneration |
| 01/29/2004 | US20040018149 Methods for cultivating dermal fibroblasts, methods for preparing in vitro dermis equivalents, methods for preparing three-dimensional in vitro skin equivalents, an in vitro dermis equivalent, a three dimensional in vitro skin |
| 01/29/2004 | CA2531176A1 Sperm cell process system |
| 01/29/2004 | CA2493255A1 Probiotics for gut neuromuscular functions |
| 01/29/2004 | CA2493182A1 Compositions and methods for treating and preventing infection |
| 01/29/2004 | CA2493062A1 Tumor treating composition and methods |
| 01/29/2004 | CA2492905A1 Method of obtaining viable human liver cells, including hepatic stem/progenitor cells |
| 01/29/2004 | CA2492805A1 Megasphaera elsdenii strain and its uses |
| 01/29/2004 | CA2489982A1 Preparation of microbial oil containing polyunsaturated fatty acids |
| 01/28/2004 | EP1384485A1 Bactericidal/permeability increasing protein or biologically active analogs thereof to treat lipopolysaccharide associated gram negative infections |
| 01/28/2004 | EP1384483A1 Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| 01/28/2004 | EP1384403A1 Adjuvant for transcutaneous immunization |
| 01/28/2004 | EP1383922A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 01/28/2004 | EP1383897A2 Self-containing lactococcus strain |
| 01/28/2004 | EP1383895A2 Polynucleotides and polypeptides of the ifnalpha-5 gene |
| 01/28/2004 | EP1383889A1 Modified organs and cells for xenotransplantation |
| 01/28/2004 | EP1383872A2 Genetically modified yt cell line and use thereof |
| 01/28/2004 | EP1383869A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
| 01/28/2004 | EP1383868A2 A method for the preparation of immunologically inert amniotic membranes |
| 01/28/2004 | EP1383867A2 Stem cell differentiation |
| 01/28/2004 | EP1383793A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/28/2004 | EP1383550A1 Scaffold matrix and tissue maintaining systems |
| 01/28/2004 | EP1383541A1 Methods for delivering nucleic acid molecules into cells and assessment thereof |
| 01/28/2004 | EP1383540A2 Methods and pharmaceutical compositions for healing wounds |
| 01/28/2004 | EP1383536A1 Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit ccr5-tropic hiv-1 infection and replication |
| 01/28/2004 | EP1383528A2 Epitope sequences |
| 01/28/2004 | EP1383524A2 Method for purifying a biological composition |
| 01/28/2004 | EP1383515A1 Activation of natural killer cells by adenosine a3 receptor agonists |
| 01/28/2004 | EP1383514A1 Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
| 01/28/2004 | EP1383513A1 Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
| 01/28/2004 | EP1383509A1 A drug for use in bone grafting |
| 01/28/2004 | EP1165102B1 Matrix protein compositions for grafting in non-mineralised tissue |
| 01/28/2004 | EP0763124B1 Method for introducing nucleic acid in higher eukaryotic cells |
| 01/28/2004 | EP0636030B1 Pasteurella haemolytica type a-1 bacterin-toxoid vaccine |
| 01/28/2004 | CN1471583A Packaging of positive-strand RNA virus replicon particles |
| 01/28/2004 | CN1471579A CRIPTO tumour polypeptide |
| 01/28/2004 | CN1471575A Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells |
| 01/28/2004 | CN1471402A Compositions and methods for diagnosis and treatment of cardiovascualr disorders |
| 01/28/2004 | CN1470631A Microbe, microbial antivirus product and its use |
| 01/28/2004 | CN1470283A Method for preparing injecta of anti-hepatitis-B-virus transspecific factor |
| 01/28/2004 | CN1470258A Chinese medicine for treating chest paralysis |
| 01/28/2004 | CN1470256A Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing |
| 01/28/2004 | CN1470251A Anti-anoxia microecological preparation and its production method |
| 01/28/2004 | CN1470250A External-use disinfecting medicinal preparation for women |
| 01/28/2004 | CN1470249A Yak-blood deproteined extract and its extraction method and use thereof |
| 01/28/2004 | CN1136011C Method and apparatus for inactivating contaminants inbiological fluid |
| 01/28/2004 | CN1136006C Externally applied chinese medicine decoction |
| 01/28/2004 | CN1136001C Medicine for treating hypertension |
| 01/28/2004 | CN1136000C Medicine for treating scleroderma and its preparing process |
| 01/28/2004 | CN1135997C Medicine for treating cardiovascular and cerebrovascular diseases |
| 01/28/2004 | CN1135995C Composite thrombolytic medicine |
| 01/28/2004 | CN1135994C Exterior-applied chinese medicine for treating gastroenteropathy, gynopathy, arthropath and sore ulcer |
| 01/28/2004 | CN1135990C Method for Preparing medicine for curing asthma |
| 01/28/2004 | CN1135989C Maternal immue secretions and their use in treatment and/or prophylaxis of conditions of human body |
| 01/28/2004 | CN1135988C Use of botulinum toxin in preparing pharmaceutical composition for treating prostatic disorders |
| 01/28/2004 | CN1135933C Multifunctional nutritive liquid and its production method |
| 01/28/2004 | CN1135927C Preparation of chlorella extract |
| 01/27/2004 | US6683170 Including peptides which selectively bound by targeted cell so that modified fiber protein is internalized by receptor-mediated endocytosis; trimerization |
| 01/27/2004 | US6683059 Constructs for suppression of oncogenic transformation, tumorigenesis and metastasis |
| 01/27/2004 | US6683057 Suppressing g beta gamma signaling; reducing intimal hyper-plasia following vein grafting and restenosis following arterial injury |
| 01/27/2004 | US6682928 Cell is transformed to express on its surface a component which binds to an fc receptor of an effector cell used as a vehicle to increase an cell lysis and phagocytosis against an antigen associated with the cell |
| 01/27/2004 | US6682907 Lentivirus have the unique capacity among retroviruses of infecting differentiated non mitotic cells and represent viral candidates of interest for the development of novel vectors |
| 01/27/2004 | US6682744 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids |
| 01/27/2004 | US6682743 Genetically engineered virus for use in the propagation of preferential cells |
| 01/27/2004 | US6682742 Vector for integration of heterologous sequences into poxviral genomes |
| 01/27/2004 | US6682737 Monoclonal antibody having the same or overlapping epitope binding specificity as that of 3e2 secreted by hybridoma atcc hb 12075 |
| 01/27/2004 | US6682730 Transplants for myocardial scars |
| 01/22/2004 | WO2004007735A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 01/22/2004 | WO2004007703A1 Replicability virus which can express anti-tumour antibody with high efficiency and the use of it |
| 01/22/2004 | WO2004007701A1 Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| 01/22/2004 | WO2004007698A1 Hemangioblast progenitor cells |
| 01/22/2004 | WO2004007697A2 Methods of implanting mesenchymal stem cells for tissue repair and formation |
| 01/22/2004 | WO2004007696A2 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| 01/22/2004 | WO2004007695A2 Lactobacilli expressing biologically active polypeptides and uses thereof |
| 01/22/2004 | WO2004007683A2 Cellular reprogramming in peptide hydrogel and uses thereof |
| 01/22/2004 | WO2004007665A2 Methods for inducing differentiation of embryonic stem cells and uses thereof |
| 01/22/2004 | WO2004007655A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
| 01/22/2004 | WO2004007654A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 01/22/2004 | WO2004006961A1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 01/22/2004 | WO2004006954A2 Transdermal botulinum toxin compositions |
| 01/22/2004 | WO2004006951A1 Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| 01/22/2004 | WO2004006942A1 Method for sustaining direct cell delivery |
| 01/22/2004 | WO2004006831A2 Method and device for inducing biological processes by micro-organs |
| 01/22/2004 | WO2004006801A2 Treatment for dry eye syndrome |
| 01/22/2004 | WO2003094837A3 Treatments with autologous fibroblast |
| 01/22/2004 | WO2003092615A3 Use of anti-cd1 antibodies for the modulation of immune responses |
| 01/22/2004 | WO2003076603A3 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions |
| 01/22/2004 | WO2003070933A3 Process of cell electrofusion |
| 01/22/2004 | WO2003068161A3 Composition and method for protecting labile active components |
| 01/22/2004 | WO2003048205A3 Novel proteins with il-6 inhibiting activity |
| 01/22/2004 | WO2003047596A3 Ointment for soothing dermatitis |
| 01/22/2004 | WO2003020889A3 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 01/22/2004 | WO2003014380A3 Microoroganisms and cells for diagnosis and therapy of tumors |
| 01/22/2004 | WO2003011359A3 Artificial pulmonary capillary |
| 01/22/2004 | WO2002069886A3 Modified proteins, designer toxins, and methods of making thereof |
| 01/22/2004 | US20040016006 Chromosome 3p21.3 genes are tumor suppressors |
| 01/22/2004 | US20040014705 Supplying polypeptides; coupling with controller; therapy for autoimmune disease |
| 01/22/2004 | US20040014635 Anticancer agents |
| 01/22/2004 | US20040014220 Using electroporation to transfer nucleotide sequences and biologicaly active molecules into peripheral human blood cells; gene therapy |